A number of firms have modified their ratings and price targets on shares of Stryker Corporation (NYSE: SYK) recently:

  • 8/26/2017 – Stryker Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/25/2017 – Stryker Corporation was upgraded by analysts at Needham & Company LLC from an “underperform” rating to a “hold” rating. They wrote, “We are upgrading SYK shares to Hold from Underperform since our thesis is not playing out as expected. SYK also announced a voluntary product recall and ship hold in its Sage Products business earlier this week. The recall was due to a cross-contamination issue with its Oral Care products and the ship hold was due to a new test required by the FDA.””
  • 8/24/2017 – Stryker Corporation had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $155.00 price target on the stock, down previously from $158.00.
  • 8/24/2017 – Stryker Corporation had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $148.00 price target on the stock.
  • 8/23/2017 – Stryker Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues. An upbeat guidance for the full year instills investor confidence on the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. Stryker has had an impressive run on the bourse over the last one year, trading above the broader industry. However, volatility in foreign currency exchange is likely to impede revenue growth. Stryker also faces supply-side headwinds and has been grappling with issues in the spine business for long. Also, China might prove to be a challenging market.”
  • 8/23/2017 – Stryker Corporation had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 8/17/2017 – Stryker Corporation was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/17/2017 – Stryker Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues. An upbeat guidance for the full year instills investor confidence in the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. Stryker has had an impressive run on the bourse over the last three months, trading above the broader industry. However, volatility in foreign currency exchange is likely to impede revenue growth. Stryker's also faces supply-side headwinds and has been grappling with issues in the spine business for long. Also, China might prove to be a challenging market.”
  • 8/1/2017 – Stryker Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $166.00 price target on the stock. According to Zacks, “Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues. An upbeat guidance for the full year instills investor confidence in the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. Stryker has had an impressive run on the bourse over the last three months, trading above the broader industry. However, volatility in foreign currency exchange is likely to impede revenue growth. Stryker's also faces supply-side headwinds and has been grappling with issues in the spine business for long. Also, China might prove to be a challenging market.”
  • 7/31/2017 – Stryker Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/30/2017 – Stryker Corporation had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $160.00 price target on the stock, up previously from $150.00.
  • 7/28/2017 – Stryker Corporation had its price target raised by analysts at Royal Bank Of Canada from $140.00 to $155.00. They now have an “outperform” rating on the stock.
  • 7/28/2017 – Stryker Corporation was given a new $148.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “hold” rating on the stock.
  • 7/28/2017 – Stryker Corporation had its price target raised by analysts at Stifel Nicolaus from $151.00 to $158.00. They now have a “buy” rating on the stock.
  • 7/27/2017 – Stryker Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “We believe Stryker's performance would be affected by supply-side headwinds, the company has been grappling with issues in the spine business for long and it is expected to affect performance in the second quarter also. Also  China might prove to be a challenging market for the company. Additionally, challenging global economic conditions and rising competition raise concerns. Meanwhile, Stryker's shares are trading at a higher valuation versus the broader Medical industry over the past three months. Estimate movement has also been mixed ahead of its second quarter earnings release. However growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. The acquisitions of Sage Products and Physio Control and the tie-up with Indo UK Institute of Health's Medicity Program are also major positives.”
  • 7/17/2017 – Stryker Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $163.00 price target on the stock. According to Zacks, “We believe Stryker's innovative product pipeline will be a key catalyst in the near term. Additionally, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. Over the past six months, Stryker outperformed the broader industry trends with respect to price performance. Additionally, the acquisitions of Sage Products and Physio Control and the tie-up with Indo UK Institute of Health's Medicity Program are major positives. On the flip side, China might prove to be a challenging market for the company. Coming to supply-side headwinds, the company has been grappling with issues in the spine business for long. We believe this may prove to be a major drawback in the quarters ahead. Additionally, challenging global economic conditions raise concerns. Stryker ended the first quarter of 2017 on a solid note, squarely beating the Zacks Consensus Estimate.”
  • 7/11/2017 – Stryker Corporation had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $140.00 price target on the stock.
  • 7/10/2017 – Stryker Corporation had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $160.00 price target on the stock, up previously from $155.00.
  • 6/30/2017 – Stryker Corporation had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $132.00 price target on the stock.

Stryker Corporation (NYSE SYK) opened at 139.57 on Tuesday. The stock has a 50 day moving average of $144.80 and a 200 day moving average of $137.03. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84. The stock has a market cap of $52.21 billion, a P/E ratio of 31.15 and a beta of 0.80.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. During the same period in the previous year, the company posted $1.39 earnings per share. Stryker Corporation’s revenue for the quarter was up 6.1% on a year-over-year basis. Equities analysts anticipate that Stryker Corporation will post $6.47 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s payout ratio is presently 37.95%.

In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the transaction, the insider now directly owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Floyd sold 7,381 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $144.70, for a total value of $1,068,030.70. The disclosure for this sale can be found here. Insiders sold 32,810 shares of company stock valued at $4,754,958 over the last three months. 7.40% of the stock is currently owned by corporate insiders.

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.